<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679935</url>
  </required_header>
  <id_info>
    <org_study_id>CRTH258ADE01</org_study_id>
    <secondary_id>2019-004767-53</secondary_id>
    <nct_id>NCT04679935</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration</brief_title>
  <acronym>FALCON</acronym>
  <official_title>A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two different&#xD;
      brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related&#xD;
      macular degeneration (AMD) who have previously received anti-VEGF (vascular endothelial&#xD;
      growth factor) treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 52-week, two arm, randomized, open-label, multicenter study in patients with&#xD;
      suboptimal anatomically controlled neovascular age-related macular degeneration. Patients who&#xD;
      consent will undergo screening assessments to evaluate their eligibility based on the&#xD;
      inclusion and exclusion criteria. Afterwards, patients will be randomized in a 1:1 ratio to&#xD;
      one of the two treatment arms and attend 15 planned visits. Subjects in the loading arm will&#xD;
      receive 3x monthly loading doses followed by treatment every 12 weeks. Subjects in the&#xD;
      non-loading arm receive one initial injection followed by treatment every 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two arm, multicenter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in best-corrected visual acuity</measure>
    <time_frame>Baseline, Week 40 to Week 52</time_frame>
    <description>Visual acuity test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean treatment interval</measure>
    <time_frame>-24 Weeks, Baseline, Week 52</time_frame>
    <description>Treatment interval distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with prolonged interval</measure>
    <time_frame>-24 Weeks, Baseline, Week 52</time_frame>
    <description>Treatment interval distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients maintained at a every 12 weeks interval</measure>
    <time_frame>every 12 weeks up to week 52</time_frame>
    <description>Treatment interval distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of patients at every 8 weeks/ every 12 weeks intervals</measure>
    <time_frame>Baseline and every 8 or 12 weeks, up tp Week 52</time_frame>
    <description>Treatment interval distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in best-corrected visual acuity</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Visual acuity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients with best-corrected visual acuity improvements of ≥ 5, ≥ 10 and ≥ 15 letters</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Visual acuity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with best-corrected visual acuity ≥ 69 letters</measure>
    <time_frame>At Week 52</time_frame>
    <description>Visual acuity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in best-corrected visual acuity</measure>
    <time_frame>Baseline, Week 16 to Week 28</time_frame>
    <description>Visual acuity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central subfield thickness</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of intraretinal fluid, subretinal fluid, and sub-retinal pigment epithelium fluid in the central subfield</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Spectral domain optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of active choroidal neovascularization leakage</measure>
    <time_frame>At Week 52</time_frame>
    <description>Fluorescein angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ocular and non-ocular adverse events</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <condition>Wet Macular Degeneration</condition>
  <condition>Retinal Degeneration</condition>
  <condition>Retinal Diseases</condition>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Brolucizumab 6 mg non-loading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One initial injection followed by treatment every 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brolucizumab 6 mg loading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 4-weekly injections followed by treatment every 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Brolucizumab</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>Brolucizumab 6 mg loading</arm_group_label>
    <arm_group_label>Brolucizumab 6 mg non-loading</arm_group_label>
    <other_name>RTH258</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent must be obtained prior to participation in the study&#xD;
&#xD;
          -  Male or female patients ≥ 50 years of age at screening&#xD;
&#xD;
          -  Active choroidal neovascularization (CNV) secondary to AMD that affects the central&#xD;
             subfield, including retinal angiomatous proliferation (RAP) with a CNV component,&#xD;
             confirmed by presence of active leakage from CNV seen by fluorescein angiography and&#xD;
             sequellae of CNV, e.g. pigment epithelial detachment (PED), subretinal or sub-retinal&#xD;
             pigment epithelium (sub-RPE) hemorrhage, blocked fluorescence, macular edema&#xD;
             (intraretinal fluid (IRF) and/or subretinal fluid (SRF) and/or sub-retinal pigment&#xD;
             epithelium (sub-RPE) fluid that affects the central subfield, as seen by spectral&#xD;
             domain optical coherence tomography (SD-OCT)) as confirmed by central reading center&#xD;
             (study eye)&#xD;
&#xD;
          -  Previous treatment with any licensed anti-VEGF (vascular endothelial growth factor)&#xD;
             drug for ≥ 6 months in a ≥ every 6 weeks to ≤ every 10 weeks injection interval with&#xD;
             residual or recurrent fluid (IRF and/or SRF) that affects the central subfield, as&#xD;
             seen by SD-OCT, despite continuous licensed anti-VEGF treatment at baseline (study&#xD;
             eye). In total, patients should not be pretreated for more than 36 months.&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) score between 83 and 38 letters, inclusive, using&#xD;
             Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at&#xD;
             both screening and baseline visit (study eye)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant conditions or ocular disorders in the study eye at screening or baseline&#xD;
             which could, in the opinion of the investigator, prevent response to study treatment&#xD;
             or may confound interpretation of study results, compromise visual acuity or require&#xD;
             planned medical or surgical intervention during the 52-week study period, atrophy or&#xD;
             fibrosis at the center of the fovea as confirmed by central reading center or&#xD;
             structural damage of the fovea (study eye)&#xD;
&#xD;
          -  Treatment with anti-VEGF drugs for &gt; 36 months.&#xD;
&#xD;
          -  Any active intraocular or periocular infection or active intraocular inflammation, at&#xD;
             screening or baseline (study eye)&#xD;
&#xD;
          -  Uncontrolled glaucoma defined as intraocular pressure (IOP) &gt; 25 mmHg on medication,&#xD;
             or according to investigator's judgment, at screening or baseline (study eye)&#xD;
&#xD;
          -  Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA&#xD;
             &lt;20/200 at screening (except when due to conditions whose surgery may improve VA, e.g.&#xD;
             cataract)&#xD;
&#xD;
          -  Ocular treatments: previous treatment with investigational drugs in the last 6 months,&#xD;
             intraocular or periocular steroids, macular laser photocoagulation, photodynamic&#xD;
             therapy, vitreoretinal surgery, intraocular surgery within 3 months prior to baseline,&#xD;
             aphakia with the absence of posterior capsule (study eye)&#xD;
&#xD;
          -  Stroke or myocardial infarction during the 6 month period prior to baseline&#xD;
&#xD;
          -  Systemic anti-VEGF therapy during the 3-month period prior to baseline&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt Main</city>
        <state>Hessen</state>
        <zip>60549</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17036</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <state>CHE</state>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD, nAMD, wet AMD, RTH258, brolucizumab, switch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on ww.clinicalstudydatarequest.com.</ipd_description>
    <ipd_url>http://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

